Xenotransplantation
This article was originally published in The Gray Sheet
Executive Summary
Recipients of xenotransplantation products "should be deferred from donation of whole blood, blood components" and other body products, according to a revision issued Oct. 18 to the 1996 Draft PHS Guidelines on Infectious Disease Issues in Xenotransplantation. The revised document, which expands the definition of xenotransplantation from "live cells, tissues, or organs from a nonhuman animal source" to include "human body fluids, cells, tissues or organs that have had ex vivo contact with live nonhuman cells, tissues, or organs," is available online (http://www.fda.gov/cber/gdlns/xenophs1000.htm)
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.